India Patent Office To Get Bayer’s Nexavar Cost Data In CL Case
This article was originally published in PharmAsia News
Executive Summary
India’s patent office expects to receive Bayer’s cost data for its Nexavar (sorafenib) for treating liver and kidney cancers when the agency holds a second hearing to consider compulsory licensing of the drug.